Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-04-17

FDA Approved: ULORIC — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ULORIC (febuxostat) submitted by Takeda Pharmaceuticals America, Inc. This action updates the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Uloric (febuxostat)

Snippet

SUPPL AP for ULORIC (FEBUXOSTAT)